A recent study has reported strong synthetic lethality between RECQL5 and an activating V617F mutation in the JAK2 tyrosine kinase in patients with myeloproliferative neoplasms, and it is possible that the JAK/STAT cascade may be worthy of further exploration in the context of NMC [63]. This evidence concerns the gene SOAT1 and myeloproliferative neoplasm.